Hemophilia B Drug Market Report

Hemophilia B Drug Market - Global Professional Analysis and Forecast to 2026

  • POSTDATE：Oct 21, 2019
  • PAGES：143
  • REPORT CODE：GMM337543
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The worldwide Hemophilia B Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 14.3% during the forecast period.

    This report presents the market size and development trends by detailing the Hemophilia B Drug market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Hemophilia B Drug market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Hemophilia B Drug industry and will help you to build a panoramic view of the industrial development.

    Hemophilia B Drug Market, By Type:

    • Type 1

    • Type 2

    • Type 3

    Hemophilia B Drug Market, By Application:

    • End-Users 1

    • End-Users 2

    • End-Users 3

    Some of the leading players are as follows:

    • REVO Biologics

    • Pfizer

    • Spark Therapeutics

    • CSL Behring

    • Sangamo BioSciences

    • Biogen

    • Emergent BioSolutions

    • Grifols

    • Dong-A Socio

    • Baxter

    • OPKO Health

    • Asklepios

    • Novo Nordisk

    • Kedrion

    • Dimension Therapeutics

    • UniQure

    • Amarna Therapeutics

    • Swedish Orphan Biovitrum

    • Alnylam Pharmaceuticals

    • Catalyst Biosciences

    Geographically, Major regions are analyzed in details are as follows:

    • North America

    • Europe

    • Asia Pacific

    • Latin America

    • Middle East & Africa

  • Table of Contents

    1 Methodology and Scope

    • 1.1 Market Segmentation & Scope

      • 1.1.1 Technology Type

      • 1.1.2 Product

      • 1.1.3 Application

      • 1.1.4 Regional scope

      • 1.1.5 Estimates and forecast timeline

    • 1.2 Research Methodology

    • 1.3 Information Procurement

      • 1.3.1 Purchased database

      • 1.3.2 Internal database

      • 1.3.3 Secondary sources

      • 1.3.4 Primary research

      • 1.3.5 Details of primary research

    • 1.4 Information or Data Analysis

      • 1.4.1 Data analysis models

    • 1.5 Market Formulation & Validation

    • 1.6 Model Details

      • 1.6.1 Commodity flow analysis

      • 1.6.2 Volume price analysis

    • 1.7 List of Secondary Sources

    • 1.8 List of Abbreviations

    2 Executive Summary

    • 2.1 Market Outlook

    • 2.2 Segment Outlook

    3 Market Variables, Trends, & Scope

    • 3.1 Market Lineage Outlook

    • 3.1.1 Parent market outlook

      • 3.1.2 Ancillary market outlook

    • 3.2 Market Segmentation

      • 3.2.1 Analysis

    • 3.3 Market Dynamics

      • 3.3.1 Market driver analysis

      • 3.3.2 Market restraint analysis

      • 3.3.3 Industry opportunities

    • 3.4 Penetration & Growth Prospect Mapping

      • 3.4.1 Penetration & growth prospect mapping analysis

    • 3.5 Business Environment Analysis Tools

      • 3.5.1 Porter's five forces analysis

      • 3.5.2 PESTLE analysis

      • 3.5.3 Major deals & strategic alliances analysis

    4 Hemophilia B Drug Market: Technology Type Analysis

    • 4.1 Hemophilia B Drug Technology Type Market Share Analysis, 2018 & 2026

    • 4.2 Hemophilia B Drug Technology Type Market: Segment Dashboard

    • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

      • 4.3.1 Type 1

      • 4.3.2 Type 2

      • 4.3.3 Type 3

    5 Hemophilia B Drug Market: Product Analysis

    • 5.1 Hemophilia B Drug Product Market Share Analysis, 2018 & 2026

    • 5.2 Hemophilia B Drug Product Market: Segment Dashboard

    • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

    6 Hemophilia B Drug Market: Application Analysis

    • 6.1 Hemophilia B Drug Application Market Share Analysis, 2018 & 2026

    • 6.2 Hemophilia B Drug Application Market: Segment Dashboard

    • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

      • 6.3.1 End-User 1

      • 6.3.2 End-User 1

      • 6.3.3 End-User 3

    7 Hemophilia B Drug Market: Regional Analysis

    • 7.1 Hemophilia B Drug Regional Market Share Analysis, 2018 & 2026

    • 7.2 Hemophilia B Drug Regional Market: Segment Dashboard

    • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

    • 7.4 List of Players at Regional Level

      • 7.4.1 North America

      • 7.4.2 Europe

      • 7.4.3 Asia Pacific

    • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

      • 7.5.1 North America

      • 7.5.2 Europe

      • 7.5.3 Asia Pacific

      • 7.5.4 Latin America

      • 7.5.5 MEA

    • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

      • 7.6.1 North America

      • 7.6.2 Europe

      • 7.6.3 Asia Pacific

      • 7.6.4 Latin America

      • 7.6.5 Middle East & Africa

    8 Competitive Analysis

    • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

    • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

    • 8.3 Vendor Landscape

      • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

    9 Company Profiles

    • 9.1 REVO Biologics

      • 9.1.1 REVO Biologics Company overview

      • 9.1.2 Financial performance

      • 9.1.3 Product benchmarking

      • 9.1.4 Strategic initiatives

      • 9.1.5 SWOT analysis

    • 9.2 Pfizer

      • 9.2.1 Pfizer Company overview

      • 9.2.2 Financial performance

      • 9.2.3 Product benchmarking

      • 9.2.4 Strategic initiatives

      • 9.2.5 SWOT analysis

    • 9.3 Spark Therapeutics

      • 9.3.1 Spark Therapeutics Company overview

      • 9.3.2 Financial performance

      • 9.3.3 Product benchmarking

      • 9.3.4 Strategic initiatives

      • 9.3.5 SWOT analysis

    • 9.4 CSL Behring

      • 9.4.1 CSL Behring Company overview

      • 9.4.2 Financial performance

      • 9.4.3 Product benchmarking

      • 9.4.4 Strategic initiatives

      • 9.4.5 SWOT analysis

    • 9.5 Sangamo BioSciences

      • 9.5.1 Sangamo BioSciences Company overview

      • 9.5.2 Financial performance

      • 9.5.3 Product benchmarking

      • 9.5.4 Strategic initiatives

      • 9.5.5 SWOT analysis

    • 9.6 Biogen

      • 9.6.1 Biogen Company overview

      • 9.6.2 Financial performance

      • 9.6.3 Product benchmarking

      • 9.6.4 Strategic initiatives

      • 9.6.5 SWOT analysis

    • 9.7 Emergent BioSolutions

      • 9.7.1 Emergent BioSolutions Company overview

      • 9.7.2 Financial performance

      • 9.7.3 Product benchmarking

      • 9.7.4 Strategic initiatives

      • 9.7.5 SWOT analysis

    • 9.8 Grifols

      • 9.8.1 Grifols Company overview

      • 9.8.2 Financial performance

      • 9.8.3 Product benchmarking

      • 9.8.4 Strategic initiatives

      • 9.8.5 SWOT analysis

    • 9.9 Dong-A Socio

      • 9.9.1 Dong-A Socio Company overview

      • 9.9.2 Financial performance

      • 9.9.3 Product benchmarking

      • 9.9.4 Strategic initiatives

      • 9.9.5 SWOT analysis

    • 9.10 Baxter

      • 9.10.1 Baxter Company overview

      • 9.10.2 Financial performance

      • 9.10.3 Product benchmarking

      • 9.10.4 Strategic initiatives

      • 9.10.5 SWOT analysis

    • 9.11 OPKO Health

      • 9.11.1 OPKO Health Company overview

      • 9.11.2 Financial performance

      • 9.11.3 Product benchmarking

      • 9.11.4 Strategic initiatives

      • 9.11.5 SWOT analysis

    • 9.12 Asklepios

      • 9.12.1 Asklepios Company overview

      • 9.12.2 Financial performance

      • 9.12.3 Product benchmarking

      • 9.12.4 Strategic initiatives

      • 9.12.5 SWOT analysis

    • 9.13 Novo Nordisk

      • 9.13.1 Novo Nordisk Company overview

      • 9.13.2 Financial performance

      • 9.13.3 Product benchmarking

      • 9.13.4 Strategic initiatives

      • 9.13.5 SWOT analysis

    • 9.14 Kedrion

      • 9.14.1 Kedrion Company overview

      • 9.14.2 Financial performance

      • 9.14.3 Product benchmarking

      • 9.14.4 Strategic initiatives

      • 9.14.5 SWOT analysis

    • 9.15 Dimension Therapeutics

      • 9.15.1 Dimension Therapeutics Company overview

      • 9.15.2 Financial performance

      • 9.15.3 Product benchmarking

      • 9.15.4 Strategic initiatives

      • 9.15.5 SWOT analysis

    • 9.16 UniQure

      • 9.16.1 UniQure Company overview

      • 9.16.2 Financial performance

      • 9.16.3 Product benchmarking

      • 9.16.4 Strategic initiatives

      • 9.16.5 SWOT analysis

    • 9.17 Amarna Therapeutics

      • 9.17.1 Amarna Therapeutics Company overview

      • 9.17.2 Financial performance

      • 9.17.3 Product benchmarking

      • 9.17.4 Strategic initiatives

      • 9.17.5 SWOT analysis

    • 9.18 Swedish Orphan Biovitrum

      • 9.18.1 Swedish Orphan Biovitrum Company overview

      • 9.18.2 Financial performance

      • 9.18.3 Product benchmarking

      • 9.18.4 Strategic initiatives

      • 9.18.5 SWOT analysis

    • 9.19 Alnylam Pharmaceuticals

      • 9.19.1 Alnylam Pharmaceuticals Company overview

      • 9.19.2 Financial performance

      • 9.19.3 Product benchmarking

      • 9.19.4 Strategic initiatives

      • 9.19.5 SWOT analysis

    • 9.20 Catalyst Biosciences

      • 9.20.1 Catalyst Biosciences Company overview

      • 9.20.2 Financial performance

      • 9.20.3 Product benchmarking

      • 9.20.4 Strategic initiatives

      • 9.20.5 SWOT analysis

     

    The List of Tables and Figures (Totals 63 Figures and 121 Tables)

    • Figure Type 1 Hemophilia B Drug market, 2015 - 2026 (USD Million)

    • Figure Type 2 Hemophilia B Drug market, 2015 - 2026 (USD Million)

    • Figure Type 3 Hemophilia B Drug market, 2015 - 2026 (USD Million)

    • Figure End-Users 1 market, 2015 - 2026 (USD Million)

    • Figure End-Users 2 market, 2015 - 2026 (USD Million)

    • Figure End-Users 3 market, 2015 - 2026 (USD Million)

    • Table List of players in North America

    • Table List of players in Europe

    • Table List of players in Asia Pacific

    • Table SWOT analysis

    • Table North America Hemophilia B Drug market, by country, 2015 - 2026 (USD Million)

    • Table North America Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table North America Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table North America Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.S. Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table U.S. Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table U.S. Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Canada Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table Canada Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table Canada Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Europe Hemophilia B Drug market, by country, 2015 - 2026 (USD Million)

    • Table Europe Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table Europe Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table Europe Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.K. Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table U.K. Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table U.K. Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Germany Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table Germany Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table Germany Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table France Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table France Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table France Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Italy Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table Italy Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table Italy Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Spain Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table Spain Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table Spain Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Asia Pacific Hemophilia B Drug market, by country, 2015 - 2026 (USD Million)

    • Table Asia Pacific Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table Asia Pacific Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table Asia Pacific Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table China Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table China Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table China Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Japan Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table Japan Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table Japan Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table India Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table India Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table India Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Latin America Hemophilia B Drug market, by country, 2015 - 2026 (USD Million)

    • Table Latin America Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table Latin America Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table Latin America Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Brazil Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table Brazil Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table Brazil Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Mexico Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table Mexico Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table Mexico Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Argentina Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table Argentina Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table Argentina Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table MEA Hemophilia B Drug market, by country, 2015 - 2026 (USD Million)

    • Table MEA Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table MEA Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table MEA Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table South Africa Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table South Africa Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table South Africa Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Nigeria Hemophilia B Drug market, by type, 2015 - 2026 (USD Million)

    • Table Nigeria Hemophilia B Drug market, by product, 2015 - 2026 (USD Million)

    • Table Nigeria Hemophilia B Drug market, by application, 2015 - 2026 (USD Million)

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Company market position analysis

    • Table Company Profiles

    • Table REVO Biologics Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Spark Therapeutics Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table CSL Behring Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Sangamo BioSciences Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Biogen Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Emergent BioSolutions Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Grifols Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Dong-A Socio Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Baxter Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table OPKO Health Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Asklepios Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Novo Nordisk Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Kedrion Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Dimension Therapeutics Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table UniQure Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Amarna Therapeutics Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Swedish Orphan Biovitrum Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Alnylam Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Catalyst Biosciences Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US